Fenebrutinib blocks the function of BTK, an enzyme that regulates B-cell development and activation ... The candidate is a ...

Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple ... allows selective inhibition of the auto-reactive B cells that are behind the pathologies of MS, myasthenia ...

Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 ...

During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK ...

Eli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has a path to market for a second after BTK inhibitor ... go-to therapy in B-cell non-Hodgkin ...

Analyst Derek Archila from Wells Fargo maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price ...

With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

“These posters, as well as an additional focus on our assay development ... the combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies, PD biomarkers related ...

BeiGene has seven presentations at IWWM 2024, and Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at ...